(Day 2 Saturday) MASAM SUD Pearls for Practice: The Future of Addiction Medicine 2024

Waltham, MA US
September 14, 2024

CREDIT ONLY COURSE 

Click on the "Program" tab to view the outline of the day 

Date & Location 

Date:   Saturday September 14, 2024
Time:  8:00 - 5:00 pm
Location:  Waltham Woods, 860 Winter Street, Waltham, MA  02451

 

Goal: 

The goal of this educational activity aims to provide participants with the necessary knowledge, skills, and attitudes to effectively recognize and treat drug use disorders and addiction comorbidities in their professional settings. Attendees can expect to gain valuable insights from experts in the field who will share their knowledge and experiences related to drug addiction treatment, including best practices, case studies, and evidence-based approaches. The coverage on Friday will include an update from BSAS, opioid use disorder, improved patient outcomes, MOTAA, expert insights, pregnancy, and billing. On Saturday, topics will include HIV, chronic pain, Buprenorphine, harm reduction, prenatal exposure, alcohol, SUD reform, and drug testing.

         

Jointly Provided by: 

Jointly Provided by the Massachusetts Society of Addiction Medicine  & Baystate Continuing Interprofessional Education

 

Target Audience

This course was designed for Physicians, Physician Assistants, Pharmacists, Nurse Practitioners, OTPs, other prescribers, and social workers.

Learning Objectives

Objectives                                                     

After participating in this educational activity, attendees should be able to:  

Top 10 Things I Get Asked about HIV/HBV/HCV from Addiction Colleagues

  • Increase clinician comfort with "non-ideal" infectious disease scenarios, notable related to chronic viral infections and the associated risks.
  • Demystify common ID topics and ensure addiction medicine professionals know that they already have exceptional ID knowledge and prowess to treat patients and reduce risks.

Chronic Pain Management

 

  • Describe the prevalence of chronic pain among people with substance use disorders, specifically opioid and alcohol use disorders.
  • Describe the harmful impact of co-occurring chronic pain on patient-centered outcomes for substance use.
  • Identify effective clinical strategies to help patients with chronic pain.  
    • a)Learn how and when to safely manage pain with opioids in patients with a history of OUD.
    • b)Learn how to select opioid medications to optimize pain relief while preserving patient safety.
    • c)Learn how to safely prescribe opioids and remain in compliance with DEA surveillance, the 2022 CDC guidelines, and other regulations.
  • Explain the need for a state-wide task force to urgently develop guidelines for the standard of care for patients with chronic pain and substance use disorders.

Innovations in Long-Acting Injectable Buprenorphine

  • Explain the pharmacology, risks and side effects of the newest form of long acting injectable buprenorphine.
  • Develop basic understanding of dosing, initiation and maintenance using weekly and monthly injectable buprenorphine.
  • Describe the differences between the different long acting injectable buprenorphine formulations.
  • Recall processes of patient selection, storage, and administration of injectable buprenorphine. 

Expert Perspectives:  Harm Reductions Updates in Massachusetts

  • Gain confidence in sharing harm reduction resources with your patients/clients.
  • Describe how safer smoking supplies can reduce risk and complications of substance use.
  • Apply effective harm reduction strategies from recent innovations, integrating these approaches into your own practice.

Assessing Protective Concerns in the Setting of Prenatal Substance Exposure:  A Trauma & Justice Informed Approach

  • Identify the basics of mandated reporting of suspected child maltreatment.
  • Recognize how families may be adversely impacted by involvement with the child welfare system. 
  • Recognize how structural racism and other intersectional forms of systemic oppression shape the epidemiology of child welfare involvement.
  • Recognize opportunities to improve safety, quality of care, policies and outcomes for families affected by substance use. 

Alcohol Use Disorder Management:  A Missed Opportunity - We Can Do Better

  • Identify risks and barriers to effective care for alcohol use disorders (AUD) in outpatient settings.
  • Identify several innovative models with potential to improve AUD outcomes and safety in outpatient settings.
  • Identify appropriate candidates for outpatient management of alcohol withdrawal syndrome.
  • Describe a protocol for outpatient management of alcohol withdrawal syndrome. 

Best Practices in Involuntary SUD Reform

  • Discuss the current state of involuntary SUD treatment in Massachusetts.
  • Analyze the potential risks of involuntary SUD treatment.
  • Gain knowledge and resources to advocate for evidenced based, person-centered SUD treatment options.

Drug Testing in Care for Substance Use Disorders:  Does it Help or Hurt?

  • Describe the chronology of drug testing and how it was integrated early on into standard care for substance use disorders.
  • Explore the impact of drug testing on patients through their direct accounts.
  • Compare the evidence for patient-centered harms and benefits of drug testing.
  • Evaluate principles of harm reduction and low-threshold care and their compatibility with routine drug testing as currently recommended and required.

 

 

 

Course summary
Available credit: 
  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 BCIPE Instructional Hours
Course opens: 
06/19/2024
Course expires: 
12/31/2024
Event starts: 
09/14/2024 - 8:00am EDT
Event ends: 
09/14/2024 - 5:00pm EDT
Cost:
$0.00
Rating: 
0

 

                                                     

Saturday, September 14

7:30 – 7:55 AM

Registration / Continental Breakfast / Exhibits

7:55 – 8:00 AM

Welcome Address

MASAM President - James Baker, MD, MPH

8:00 – 8:30 AM

Top 10 Things I Get Asked About HIV/HBV/HCV from Addiction Colleagues

Dr. Joshua St. Louis, MD, MPH, FAAFP, FASAM, AAIVS

8:30 – 9:30 AM

Chronic Pain Management

James Baker, MD, MPH; Natalie Stahl, MD, MPH

9:30 – 9:45 AM

Break / Networking / Exhibits

9:45 – 10:45 AM

Innovations in Long-Acting Injectable Buprenorphine

Emily W. Marcus, MSN, FNP-C, PMHNP-BC, CARN-AP

10:45 – 11:45 AM

Expert Perspectives: Harm Reductions Updates in Massachusetts

Moderator: Jessica Gray, MD

11:45 AM – 12:40 PM

Lunch Break / MASAM Business Meeting

12:40 – 12:45 PM

Presentation of the Dr. Barbara Herbert Award

12:45 – 1:45 PM

Assessing Protective Concerns in the Setting of Prenatal Substance Exposure: A Trauma & Justice Informed Approach

Elizabeth Egan, MPH, LICSW; Heather Hsu, MD MPH; Genevieve Preer, MD

1:45 – 2:30 PM

Alcohol Use Disorder Management: A Missed Opportunity – We Can Do Better

Emily Hurstak, MD, MPH, MAS; Alyssa F. Peterkin, MD

2:30 – 2:45 PM

Break / Networking / Exhibits

2:45 – 3:45 PM

Best Practices in Involuntary SUD Reform

Deborah R. Goldfarb, LICSW

3:45 – 5:00 PM

Drug Testing in Care for Substance Use Disorders: Does it Help or Hurt?

Stephen A. Martin, MD, EdM, FAAFP, FASAM

 

 

 

 

 

 

 

Conference Center at Waltham Woods
860 Winter Street
Waltham, MA 02451
United States

FACULTY

Name of Individual

Individual's Role in Activity

Financial Relationship Disclosure

Discussion of
Unlabeled/Unapproved
Uses of Drugs/Devices
in Presentation?

Todd Kerensky, MDPlanning Committee Member            No relevant relationships with ineligible companies to disclose       No
James Baker, MD, MPH         Planning Committee Member & Speaker      No relevant relationships with ineligible companies to discloseNo
Jessica Gray, MDPlanning Committee Member & SpeakerNo relevant relationships with ineligible companies to discloseNo
Ruth A. Potee, MDPlanning Committee MemberNo relevant relationships with ineligible companies to discloseNo
Heidi Ginter, MDPlanning Committee MemberNo relevant relationships with ineligible companies to discloseNo
Joshua St. Louis, MD, MPHSpeakerNo relevant relationships with ineligible companies to discloseNo
Emery Marcus, MSNSpeakerNo relevant relationships with ineligible companies to discloseNo
Stephen Martin, MDSpeakerNo relevant relationships with ineligible companies to discloseNo
Heather Hsu, MDSpeakerNo relevant relationships with ineligible companies to discloseNo
Elizabeth Egan, LICSWSpeakerNo relevant relationships with ineligible companies to discloseNo
Genevieve Preer, MDSpeakerNo relevant relationships with ineligible companies to discloseNo
Emily Hurstak, MDSpeakerNo relevant relationships with ineligible companies to discloseNo
Alyssa Peterkin, MDSpeakerNo relevant relationships with ineligible companies to discloseNo
Deb Goldfarb, LICSWSpeakerNo relevant relationships with ineligible companies to discloseNo

 

 

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the other planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians

Baystate Continuing Interprofessional Education designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit(s)TM.  Physicians should only claim the credit commensurate with the extent of their participation in the activity.  

Risk Management 
This activity meets the criteria for Risk Management study.  7.50 hour is appropriate for risk management study.  

 

Available Credit

  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 BCIPE Instructional Hours

Price

Cost:
$0.00
Please login or register to take this course.

 

Please Note: In order for your registration to be considered complete:
  • Each participant must register themselves for the program.

 

In order to receive CREDIT, the evaluation must be completed by:Tue, 12/31/2024 - 3:30pm

We appreciate your business and sincerely wish to meet your educational needs.  We understand that the schedule of a busy professional, like yourself, is subject to change.  Therefore, we have included information about our refund/cancellation policies for your convenience below.

Cancellation:
If you must cancel, telephone Baystate Continuing Interprofessional Education at 413-322-4242 and follow your call with a written/email request. 

Specific Aids or Services:
Please call Baystate Continuing Interprofessional Education at 413-322-4242 if, under the Americans with Disabilities Act, you require specific aids or services during your visit to this continuing education program.